drugset / Trial / NCT04844424

A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants

NCT04844424

Phase 1 Completed 115 enrolled Janssen Research & Development, LLC
RandomizedCrossoverOpen-labelOther

Summary

The purpose of this study is to evaluate the relative bioavailability and food effect of a single dose of milvexian administered as direct compression (DC) oral tablets and roller compacted (RC) oral tablets compared with milvexian administered as Phase 2 oral capsules (Part 1) and of new concept tablets consisting of a single dose of milvexian administered as oral Tablet 1 and Tablet 2 compared with milvexian administered as Phase 2 oral capsules (Part 3) in healthy participants under fasting and fed conditions; to characterize the pharmacokinetics (PK) of multiple twice daily (BID) doses for 5 days of milvexian administered as DC oral tablets and Phase 2 oral capsules in healthy participants (Part 2) and to assess the effects of dosing time and food timing on the PK of single-dose of milvexian Phase 3 oral tablet formulation in healthy participants (Part 4) and to evaluate the relative bioavailability of a single dose of milvexian administered as oral film-coated DC whole tablets, oral film-coated DC tablets dispersed in water and then mixed with apple sauce, and oral film-coated DC tablets dispersed in water and administered as a suspension using a nasogastric (NG) tube in healthy participants under fasting conditions (Part 5).

Timeline

Start
2021-04-14
Primary completion
2022-05-06
Completion
2022-07-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Milvexian Small molecule Oral

Indications

No indication recorded.